Suppr超能文献

2020 年 3 月 1 日至 2021 年 6 月 28 日期间,年龄<18 岁的 SARS-CoV-2 感染者在新冠病毒感染后 30 天以上新发糖尿病的风险。

Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years - United States, March 1, 2020-June 28, 2021.

出版信息

MMWR Morb Mortal Wkly Rep. 2022 Jan 14;71(2):59-65. doi: 10.15585/mmwr.mm7102e2.

Abstract

The COVID-19 pandemic has disproportionately affected people with diabetes, who are at increased risk of severe COVID-19.* Increases in the number of type 1 diabetes diagnoses (1,2) and increased frequency and severity of diabetic ketoacidosis (DKA) at the time of diabetes diagnosis (3) have been reported in European pediatric populations during the COVID-19 pandemic. In adults, diabetes might be a long-term consequence of SARS-CoV-2 infection (4-7). To evaluate the risk for any new diabetes diagnosis (type 1, type 2, or other diabetes) >30 days after acute infection with SARS-CoV-2 (the virus that causes COVID-19), CDC estimated diabetes incidence among patients aged <18 years (patients) with diagnosed COVID-19 from retrospective cohorts constructed using IQVIA health care claims data from March 1, 2020, through February 26, 2021, and compared it with incidence among patients matched by age and sex 1) who did not receive a COVID-19 diagnosis during the pandemic, or 2) who received a prepandemic non-COVID-19 acute respiratory infection (ARI) diagnosis. Analyses were replicated using a second data source (HealthVerity; March 1, 2020-June 28, 2021) that included patients who had any health care encounter possibly related to COVID-19. Among these patients, diabetes incidence was significantly higher among those with COVID-19 than among those 1) without COVID-19 in both databases (IQVIA: hazard ratio [HR] = 2.66, 95% CI = 1.98-3.56; HealthVerity: HR = 1.31, 95% CI = 1.20-1.44) and 2) with non-COVID-19 ARI in the prepandemic period (IQVIA, HR = 2.16, 95% CI = 1.64-2.86). The observed increased risk for diabetes among persons aged <18 years who had COVID-19 highlights the importance of COVID-19 prevention strategies, including vaccination, for all eligible persons in this age group, in addition to chronic disease prevention and management. The mechanism of how SARS-CoV-2 might lead to incident diabetes is likely complex and could differ by type 1 and type 2 diabetes. Monitoring for long-term consequences, including signs of new diabetes, following SARS-CoV-2 infection is important in this age group.

摘要

COVID-19 大流行对糖尿病患者造成了不成比例的影响,这些患者患严重 COVID-19 的风险增加。在 COVID-19 大流行期间,欧洲儿科人群中报告了 1 型糖尿病诊断数量增加(1,2)和糖尿病诊断时糖尿病酮症酸中毒(DKA)的频率和严重程度增加(3)。在成年人中,糖尿病可能是 SARS-CoV-2 感染的长期后果(4-7)。为了评估 SARS-CoV-2 急性感染后 30 天以上任何新发糖尿病诊断(1 型、2 型或其他糖尿病)的风险,CDC 使用 IQVIA 医疗保健索赔数据从 2020 年 3 月 1 日至 2021 年 2 月 26 日构建回顾性队列估计了<18 岁(患者)COVID-19 患者的糖尿病发病率,比较了 1)未在大流行期间接受 COVID-19 诊断或 2)接受大流行前非 COVID-19 急性呼吸道感染(ARI)诊断的年龄和性别相匹配的患者的发病率。使用第二个数据源(HealthVerity;2020 年 3 月 1 日至 2021 年 6 月 28 日)复制了分析,该数据源包括可能与 COVID-19 相关的任何医疗保健就诊的患者。在这些患者中,与 1)两个数据库中没有 COVID-19 的患者(IQVIA:危险比[HR] = 2.66,95%CI = 1.98-3.56;HealthVerity:HR = 1.31,95%CI = 1.20-1.44)和 2)大流行前非 COVID-19 ARI 的患者相比,COVID-19 患者的糖尿病发病率显着更高(IQVIA,HR = 2.16,95%CI = 1.64-2.86)。<18 岁患有 COVID-19 的人群中观察到的糖尿病风险增加,突显了 COVID-19 预防策略的重要性,包括为该年龄组的所有合格人群接种疫苗,以及慢性病的预防和管理。SARS-CoV-2 如何导致新发糖尿病的机制可能很复杂,并且可能因 1 型和 2 型糖尿病而有所不同。在该年龄组中,监测 SARS-CoV-2 感染后的长期后果(包括新糖尿病的迹象)很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/444d/8757617/9293d84c00ce/mm7102e2-F.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验